Literature DB >> 19959102

Is there a role for maintenance therapy in acute myeloid leukaemia?

Maria R Baer1.   

Abstract

Maintenance therapy is not part of current standard treatment for acute myeloid leukaemia (AML). However, in other leukaemias, maintenance therapy is used to prolong responses and increase the cure rate. While maintenance chemotherapy has not been shown to improve outcome in AML, several other maintenance strategies are currently being tested in this disease, including immunotherapy, demethylating agents and targeted therapies. While maintenance chemotherapy does not appear to have a role in AML curative therapy, the novel maintenance strategies currently being tested appear promising and warrant further study.

Entities:  

Mesh:

Year:  2009        PMID: 19959102     DOI: 10.1016/j.beha.2009.09.001

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  5 in total

Review 1.  Histamine dihydrochloride: in the management of acute myeloid leukaemia.

Authors:  Lily P H Yang; Caroline M Perry
Journal:  Drugs       Date:  2011-01-01       Impact factor: 9.546

Review 2.  Optimal therapy for adult patients with acute myeloid leukemia in first complete remission.

Authors:  Peter H Wiernik
Journal:  Curr Treat Options Oncol       Date:  2014-06

3.  Oral Maintenance Chemotherapy with 6-Mercaptopurine and Methotrexate in Patients with Acute Myeloid Leukemia Ineligible for Transplantation.

Authors:  Yong Won Choi; Seong Hyun Jeong; Mi Sun Ahn; Hyun Woo Lee; Seok Yun Kang; Jin-Hyuk Choi; Joon Seong Park
Journal:  J Korean Med Sci       Date:  2015-09-12       Impact factor: 2.153

4.  Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia.

Authors:  Gail J Roboz; Pau Montesinos; Dominik Selleslag; Andrew Wei; Jun-Ho Jang; Jose Falantes; Maria T Voso; Hamid Sayar; Kimmo Porkka; Paula Marlton; Antonio Almeida; Sanjay Mohan; Farhad Ravandi; Guillermo Garcia-Manero; Barry Skikne; Hagop Kantarjian
Journal:  Future Oncol       Date:  2016-01-19       Impact factor: 3.404

5.  Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant.

Authors:  Brenda M Sandmaier; Samer Khaled; Betül Oran; Guy Gammon; Denise Trone; Olga Frankfurt
Journal:  Am J Hematol       Date:  2017-11-17       Impact factor: 10.047

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.